Literature DB >> 8829821

Disparate effects of calcium antagonists on renal microcirculation.

K Hayashi1, T Nagahama, K Oka, M Epstein, T Saruta.   

Abstract

Although calcium antagonists reduce systemic blood pressure, the effects of calcium antagonists on renal preglomerular and postglomerular microcirculation have been suggested to differ. In the present study we examined the vasodilator action of dihydropyridine-type calcium antagonists, including nifedipine, nicardipine, amlodipine, and efonidipine, on afferent and efferent arterioles during angiotensin II (A-II)- and norepinephrine (NE)-induced renal vasoconstriction. Isolated perfused hydronephrotic kidneys were used to directly visualize renal microcirculatory response to calcium antagonists. Both A-II and NE caused marked vasoconstriction of afferent (A-II, 27 +/- 2% decrement; NE, 28 +/- 2% decrement) and efferent arterioles (A-II, 25 +/- 4% decrement; NE, 22 +/- 2% decrement). The subsequent addition of nifedipine, nicardipine, and amlodipine reversed the afferent arteriolar vasoconstriction in a dose-dependent manner, and elicited complete vasodilation at 10(-6) M. In contrast, efferent arteriolar vasoconstriction was relatively refractory to the dilator action of these calcium antagonists; maximal dilation observed at 10(-6) M was 21 +/- 1% (A-II) and 22 +/- 3% (NE) for nifedipine, 25 +/- 3% (A-II) and 20 +/- 6% (NE) for nicardipine, and 39 +/- 6% (A-II) and 37 +/- 3% (NE) for amlodipine. In striking contrast, efonidipine dilated not only afferent arterioles, but also efferent arterioles in a dose-dependent manner. At 10(-6) M, efonidipine completely inhibited the afferent (A-II, 89 +/- 7% reversal; NE, 99 +/- 8% reversal) and efferent arteriolar vasoconstriction (A-II, 93 +/- 4% reversal; NE, 87 +/- 9% reversal). These findings clearly demonstrate that calcium antagonists dilate the afferent arteriole. Unlike the effects on the afferent arteriole, efferent arteriolar responsiveness to calcium antagonists differ, depending on the type of calcium antagonist. The efonidipine-induced efferent arteriolar vasodilation is probably not related to voltageoperated calcium channels, and may act, in concert with blood pressure lowering effect, to ameliorate glomerular capillary hypertension.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8829821     DOI: 10.1291/hypres.19.31

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  18 in total

1.  Voltage-gated divalent currents in descending vasa recta pericytes.

Authors:  Zhong Zhang; Hai Lin; Chunhua Cao; Sandeep Khurana; Thomas L Pallone
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-14

Review 2.  Vascular effects of calcium channel antagonists: new evidence.

Authors:  Sylvain Richard
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.

Authors:  Narutaka Ohashi; Hideo Mitamura; Satoshi Ogawa
Journal:  Drugs       Date:  2009       Impact factor: 9.546

4.  Hyperoxaluria-induced tubular ischemia: the effects of verapamil on the antioxidant capacity of the affected kidneys.

Authors:  Kemal Sarica; Alper Kafkasli; Fehmi Narter; Oguz Ozturk; Ozgur Yazici; Bilal Hamarat; Cahit Sahin; Bilal Eryildirim
Journal:  Urolithiasis       Date:  2016-06-09       Impact factor: 3.436

5.  Use of calcium antagonists and worsening renal function in patients receiving angiotensin-converting-enzyme inhibitors.

Authors:  Giuseppe Zuccalà; Graziano Onder; Claudio Pedone; Matteo Cesari; Emanuele Marzetti; Alberto Cocchi; Pierugo Carbonin; Roberto Bernabei
Journal:  Eur J Clin Pharmacol       Date:  2003-01-31       Impact factor: 2.953

6.  Effect of verapamil on urinary stone-forming risk factors.

Authors:  Kemal Sarica; Sakip Erturhan; Bulent Altay
Journal:  Urol Res       Date:  2006-12-13

7.  Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.

Authors:  Kyle H Moore; John S Clemmer
Journal:  Am J Physiol Renal Physiol       Date:  2021-09-06

8.  Analysis of Risk Factors for High-dose Cisplatin-induced Renal Impairment in Head and Neck Cancer Patients.

Authors:  Hiroyoshi Koide; Satoshi Noda; Yumi Okunuki; Shigehiro Owaki; Takeshi Shimizu; Tomohiro Terada; Shin-Ya Morita
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

9.  New Generation Calcium Channel Blockers in Hypertensive Treatment.

Authors:  Yuri Ozawa; Koichi Hayashi; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006-05-01

10.  Dihydropyridine calcium channel blockers in the elderly with diabetic nephropathy: Are they safe?

Authors:  Zeid J Khitan; Antonios H Tzamaloukas; Sergey Brodsky; Joseph I Shapiro
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-01-06       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.